2025. Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s688. DOI:https://doi.org/10.25251/jy4cvn36.